Kimia Biosciences is currently trading at Rs. 40.40, up by 1.50 points or 3.86% from its previous closing of Rs. 38.90 on the BSE.
The scrip opened at Rs. 39.00 and has touched a high and low of Rs. 40.80 and Rs. 38.15 respectively. So far 733 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 1 has touched a 52 week high of Rs. 64.45 on 06-Jan-2021 and a 52 week low of Rs. 19.50 on 07-Apr-2020.
Last one week high and low of the scrip stood at Rs. 42.00 and Rs. 37.95 respectively. The current market cap of the company is Rs. 191.14 crore.
The promoters holding in the company stood at 74.94%, while Institutions and Non-Institutions held 0.38% and 24.68% respectively.
Kimia Biosciences has been granted permission to manufacture new API for sale or for distribution' namely Bilastine by Central Drugs Standard Control Organization, Ministry of Health & Family Welfare, FDA Bhawan, New Delhi.
Kimia Biosciences is a pharmaceutical company and the state of the art manufacturing facility is manufacturing latest Bulk Drugs and intermediates (R&D based) for India and Overseas markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: